Discussing The Past, Present And Future Of Cell And Gene Therapies
Outgoing CEO Of The Cell and Gene Therapy Catapult, Keith Thompson, On Turning Groundbreaking Research Into A New Industry
Founding CEO of the UK’s Cell and Gene Therapy Catapult, Keith Thompson, will retire from the company this year. He looks back on the last eight years of progress for CGT Catapult and the advanced therapies sector – and provides words of wisdom for the challenges still to come.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.